Despite all the excitement surrounding CAR T treatments, there are a number of formidable challenges facing the field including: continuing to improve the efficacy and persistence of CAR T therapy; minimise the long manufacturing durations, improve understanding and measurement of critical quality attributes of the CAR T-cells; lowering the cost of treatment and development of more efficacious CAR T-cells for targeting solid tumours.
Solid tumours constitute more than 90% of all cancers and there are various factors including the immunosuppressive tumour microenvironment, the heterogeneity of the tumour population and the infiltration and trafficking of the CAR T-cells to the tumour site, which collectively makes it challenging to develop efficacious CAR T therapy. It is imperative that we continue to improve on our understanding of tumour biology and its interaction with the immune system in order to develop more efficacious CAR T therapies against solid tumours.
Yama Abassi at Agilent
https://www.iptonline.com/collections/ipt-winter-2023/real-time-cell-analysis
The start of the modern and emerging field of immuno-oncology can be traced back to the US Food and Drug Administration (FDA) approval of the first immune checkpoint inhibitor, ipilimumab, back in 2011. Since then, a number of immuno-oncology therapies based on different modalities have been approved by the FDA, which collectively has ushered in a new era of cancer treatment. These new treatments have already become standard of care for several different types of cancer indications.
No comments:
Post a Comment